PORT WASHINGTON, N.Y., April 19, 2010 - Pharmaceutical and biotechnology manufacturers will gather this week at INTERPHEX 2010 in search of answers to help streamline operations and boost profit margins. In response, Pall Corporation (NYSE: PLL) is introducing ground-breaking technologies and expanded service offerings to help manufacturers improve their products and processes. A global leader in filtration, separation and purification for life sciences, Pall Corporation will be exhibiting in booth 2006 at INTERPHEX which is being held April 20-22 in New York’s Jacob B. Javits Center.
Highlights of Pall’s product announcements at the show include:
The Cadence™ system, the industry’s first single-pass tangential flow filtration (TFF) technology, eliminates the recirculation loop and streamlines operations to optimize downstream processing.The patented Cadence TFF system harnesses a new TFF format, the Cadence module, which enables direct flow operation with a substantial reduction in system hold-up volume. This, along with improved recovery capabilities, yields product recoveries greater than 98 percent. The technology is designed for single-use or re-use modes of operation.
The Palltronic® Flowstar IV integrity test instrument offers improved pressure/flow calibration to preserve measurement accuracy while ensuring a faster testing process. Lightweight, compact and ergonomic, the newly designed instrument also features an enhanced touchscreen and user-friendly interface.
Supra™ AKS depth purification filters are new intermediate-size cartridges that give process developers important scale-up options when using Pall's line of depth filters featuring Seitz® AKS immobilized activated carbon depth filter media. The new sizes add process design flexibility and streamline operations.
T-series TFF cassettes offer more durable, stable materials that exhibit low extractables and offer broad chemical compatibility to increase process safety, reliability and reproducibility. The cassettes feature Pall’s proven Omega™ PES and Delta regenerated cellulose membranes to reduce revalidation requirements.
Pall is also enhancing the validation and instrumentation services offered through its Scientific and Laboratory Services (SLS) Group to deliver more consistent responsive global support. As companies look to outsource more tasks, Pall can help assure product quality, manufacturing processes and regulatory requirements are met.
“We are working to apply the latest technologies and services to our customers’ operations, so they have the optimal tools and expertise to bring new and innovative drugs to market more efficiently,” said Ken Frank, president of Pall Life Sciences biopharmaceuticals division. “Our people and products support customer operations from upstream through downstream while also facilitating their ability to comply with increasingly rigorous global requirements.”
Pall Life Sciences provides cutting-edge products and services to meet the demanding needs of customers discovering, developing and producing biotech drugs, vaccines and classic pharmaceuticals. Pall technologies are also used to collect and process blood components and help protect patients from hospital-acquired infections. The company’s membranes and membrane devices optimize detection and sample preparation in the drug research, clinical diagnostics, genomics and proteomics markets. Pall is a leading provider of separation systems, and single-use filtration and purification technologies to pharmaceutical and biotechnology companies to support faster development of new drugs and vaccines that are safer, and require less energy and water to produce.
About Pall Corporation
Pall Corporation (NYSE: PLL) is a filtration, separation and purification leader providing Total Fluid ManagementSM solutions to meet the critical needs of customers in biopharmaceutical; hospital, transfusion and veterinary medicine; energy and alternative energy; electronics; municipal and industrial water; aerospace; transportation and broad industrial markets. Together with our customers, we foster health, safety and environmentally responsible technologies. The company’s engineered solutions enable process and product innovation and minimize emissions and waste. Pall Corporation, with total revenues of $2.3 billion for fiscal 2009, is an S&P 500 company with more than 10,000 employees servicing customers worldwide. Pall has been named a top "green company" by Newsweek magazine. To see how Pall is helping enable a greener and more sustainable future, visit www.pall.com.
Pall Life Sciences
Carol Flint, 734-913-6432
Global V.P. Marketing Communications email@example.com